Tissue inhibitor of metalloproteinases (TIMPs) in heart failure

被引:32
作者
Linn Moore
Dong Fan
Ratnadeep Basu
Vijay Kandalam
Zamaneh Kassiri
机构
[1] University of Alberta,Department of Physiology, Cardiovascular Research Centre, Mazankowski Alberta Heart Institute
来源
Heart Failure Reviews | 2012年 / 17卷
关键词
Heart failure; Extracellular matrix; Remodeling; Tissue inhibitor of metalloproteinases; Matrix metalloproteinases;
D O I
暂无
中图分类号
学科分类号
摘要
Remodeling of the myocardium and the extracellular matrix (ECM) occurs in heart failure irrespective of its initial cause. The ECM serves as a scaffold to provide structural support as well as housing a number of cytokines and growth factors. Hence, disruption of the ECM will result in structural instability as well as activation of a number of signaling pathways that could lead to fibrosis, hypertrophy, and apoptosis. The ECM is a dynamic entity that undergoes constant turnover, and the integrity of its network structure is maintained by a balance in the function of matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitor of metalloproteinases (TIMPs). In heart disease, levels of MMPs and TIMPs are altered resulting in an imbalance between these two families of proteins. In this review, we will discuss the structure, function, and regulation of TIMPs, their MMP-independent functions, and their role in heart failure. We will review the knowledge that we have gained from clinical studies and animal models on the contribution of TIMPs in the development and progression of heart disease. We will further discuss how ECM molecules and regulatory genes can be used as biomarkers of disease in heart failure patients.
引用
收藏
页码:693 / 706
页数:13
相关论文
共 414 条
[1]
Hunt SA(2005)ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society
[2]
Abraham WT(2000)Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling Cardiovasc Res 46 214-224
[3]
Chin MH(2007)Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function Physiol Rev 87 1285-1342
[4]
Li YY(2009)Matrix metalloproteinase therapy in heart failure Curr Treat Options Cardiovasc Med 11 339-346
[5]
McTiernan CF(2001)Integrins and the myocardium Circ Res 88 1112-1119
[6]
Feldman AM(2006)Integrins, membrane-type matrix metalloproteinases and ADAMs: potential implications for cardiac remodeling Cardiovasc Res 69 574-584
[7]
Spinale FG(1995)Role of the alpha 1 beta 1 integrin complex in collagen gel contraction in vitro by fibroblasts J Cell Physiol 165 425-437
[8]
Spinale FG(2004)Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation Crit Rev Clin Lab Sci 41 233-264
[9]
Wilbur NM(1998)Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds Circulation 98 1699-1702
[10]
Ross RS(2008)Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction Eur J Heart Fail 10 133-139